Nearly 200 Late Stage Products Soon to Impact Biopharma Market

13 Jun 2011 • by Natalie Aster

New YorkA full biologics pipeline will lead to continued growth in the biopharmaceutical market, according to Kalorama Information. The healthcare market research firm expects annual growth of 7.1% through 2015, given the nearly 200 products in late-stage development. According to the latest report “ What's Next in Biologics (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015” by Kalorama Information the top five biopharmaceutical companies continue to dominate this market landscape.

A majority of the 200 biologics currently in the development pipeline are aimed at the treatment of cancers, followed by cardiovascular diseases and autoimmune and hormone disorders. According to the report, monoclonal antibodies account for the largest share of the innovation with nearly thirty new antibody compounds in development. Multiple companies expecting to profit from the products currently in late-stage development, each of which can cost $1-2 billion to develop, are driving the market's growth through 2015, when Kalorama expects it to reach just under $150 billion.

Report Details:

What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015

Published: May 2011

Pages: 150

Price: US$ 3,995

"The Phase III pipelines are heavy in this area and that will keep growth up," said Bruce Carlson, publisher of Kalorama Information. "The beneficiaries will be a number of companies, though especially the top five. Although a number of smaller companies are operating in this market, difficulties remain in overcoming the high cost of development. "

The report details several companies, but indicates that the biologics market is still dominated by the top five pharmaceutical companies—Amgen, GlaxoSmithKline, Novartis, Pfizer and Roche—which combined hold over a quarter of the late-stage products.

"The big players have a steady flow of new products and extensions coming through the pipeline, with over 100 projects in development," added Carlson. "The strongest pipeline is still held by Roche's Genetech."

More information can be found in the report “What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015” by Kalorama Information. The report looks at the market for non-vaccine biological drugs and the companies that compete in the market. It discusses the biopharmaceutical pipeline for major companies and provides market size estimates and forecasts for monoclonal antibodies, recombinant hormones and proteins, interferons and other biologics.

To order the report or ask for sample pages contact



MarketPublishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970